Differential activation of Fas (CD95) mediated apoptosis by apple procyanidins in human colon cancer cells SW480 and their derived metastatic cells SW620
Article Sidebar
Main Article Content
Methods: Pcy were characterized by reverse-phase HPLC. Cell death, Fas proteins, DNA fragmentation, and mitochondrial membrane potential were analyzed by flow cytometry. Fas mRNA was analyzed by RT-PCR in real time.
Results: Pcy up-regulated the expression of the Fas receptor at the cell surface of both cell lines but activated Fas gene transcription only in SW620 cells. In SW480 cells, Pcy combined with Fas agonist CH-11 enhanced Fas-mediated apoptosis involving the loss of mitochondrial membrane potential and DNA fragmentation, which were abrogated by the antagonist antibody of Fas receptor, the anti-Fas ZB4. On the contrary, in SW620 cells, CH-11 was not able to enhance Pcy-triggered apoptosis indicating that Fas receptor-mediated apoptosis was not activated in these cells despite an up-regulation of Fas receptor gene expression. However, it was observed in SW620 cells that Pcy activated the Fas receptor-mediated apoptotic pathway after a specific blockage of TRAIL-death DR4/DR5 receptors.
Conclusions: The present data showed that Pcy were able to activate the Fas receptor apoptotic pathway in SW480 cells and favored a cross-talk between TRAIL and Fas receptors in SW620 cells because specific blocking of TRAIL death receptors favored activation of the Fas receptor-mediated apoptosis. These important data may allow the emergence of new therapeutic protocols targeting death receptors against resistant metastatic cells.
- Apoptosis
- Colorectal cancer
- Flavonoids
- Procyanidins
- Fas
- TRAIL
Van Breda SG, de Kok TM, van Delft JH. Mechanisms ofcolorectal and lung cancer prevention by vegetables: a genomicapproach. J Nutr Biochem. 2008; 19: 139-57.2.Gerhauser C. Cancer chemopreventive potential of apples,apple juice, and apple components. Planta Med. 2008; 74:1608-24.3.Gossé F, Guyot S, Roussi S, Lobstein A, Fischer B, Seiler N,et al. Chemopreventive properties of apple procyanidins onhuman colon cancer-derived metastatic SW620 cells and in arat model of colon carcinogenesis. Carcinogenesis. 2005; 26:1291-5.4.Maldonado-Celis ME, Roussi S, Foltzer-Jourdainne C, GosséF, Lobstein A, Habold C, et al. Modulation by polyamines ofapoptotic pathways triggered by procyanidins in humanmetastatic SW620 cells. Cell Mol Life Sci. 2008; 65: 1425-34.5.Maldonado-Celis M, Bousserouel S, Gossé F, Minker C,Lobstein A, Raul F. Differential induction of apoptosis byapple procyanidins in TRAIL-sensitive human colon tumorcells and derived TRAIL-resistant metastatic cells. J CancerMol. 2009; 5: 21-30.6.Strasser A, Jost PJ, Nagata S. The many roles of FAS receptorsignaling in the immune system. Immunity 2009; 30: 180-92.7.Bergmann-Leitner ES, Abrams SI. Differential role of Fas/Fasligand interactions in cytolysis of primary and metastaticcolon carcinoma cell lines by human antigen-specific CD8+CTL. J Immunol. 2000; 164: 4941-54.8.O’Connell J, Bennett MW, Nally K, Houston A, O’SullivanGC, Shanahan F. Altered mechanisms of apoptosis in coloncancer: Fas resistance and counterattack in the tumor-immuneconflict. Ann NY Acad Sci. 2000; 910: 178-92.9.Bhushan A, Kupperman JL, Stone JE, Kimberly PJ, CalmanNS, Hacker MP, et al. Drug resistance results in alterations inexpression of immune recognition molecules and failure toexpress Fas (CD95). Immunol Cell Biol. 1998; 76: 350-6.10. Souquet JM, Labarbe B, Le Guerneve C, Cheynier V,Moutounet M. Phenolic composition of grape stems. J AgricFood Chem. 2000; 48: 1076-80.11. Livak KJ, Schmittgen TD. Analysis of relative gene expressiondata using real-time quantitative PCR and the 2(-Delta DeltaC(T)) method. Methods. 2001; 25: 402-8.12. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, RiccardiC. A rapid and simple method for measuring thymocyteapoptosis by propidium iodide staining and flow cytometry. JImmunol Methods. 1991; 139: 271-9.13. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification ofprogrammed cell death in situ via specific labeling of nuclearDNA fragmentation. J Cell Biol. 1992; 119: 493-501.14. Huerta S, Heinzerling JH, Anguiano-Hernández YM, Huerta-Yepez S, Lin J, Chen D, et al. Modification of gene productsinvolved in resistance to apoptosis in metastatic colon cancercells: roles of Fas, Apaf-1, NFkB, IAPs, Smac/DIABLO, andAIF. J Surg Res. 2007; 142: 184-94.15. Li Y, Yang X, Nguyen AH, Brockhausen I. Requirement ofN-glycosylation for the secretion of recombinant extracellulardomain of human Fas in HeLa cells. Int J Biochem CellBiol. 2007; 39: 1625-36.16. Russo M, Nigro P, Rosiello R, D’Arienzo R, Russo GL.Quercetin enhances CD95- and TRAIL-induced apoptosis inleukemia cell lines. Leukemia. 2007; 21: 1130-3.17. Huang DC, Tschopp J, Strasser A. Bcl-2 does not inhibit celldeath induced by the physiological Fas ligand: implicationsfor the existence of type I and type II cells. Cell Death Differ.2000; 7: 754-5.18. Clemons NJ, Buzzard K, Steel R, Anderson RL.Hsp72 inhibitsFas-mediated apoptosis upstream of the mitochondria in typeII cells. J Biol Chem. 2005; 280: 9005-12.19. Henson ES, Gibson EM, Villanueva J, Bristow NA, Haney N,Gibson SB.Increased expression of Mcl-1 is responsible forthe blockage of TRAIL-induced apoptosis mediated by EGF/ErbB1 signaling pathway. J Cell Biochem. 2003; 89:1177-92.20. Thomas LR, Johnson RL, Reed JC, Thorburn A. The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposingfunctions in Fas-associated death domain (FADD) recruitmentand can regulate agonist-specific mechanism of receptoractivation. J Biol Chem. 2004; 279: 52479-86.
Downloads
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use